中文

← All funding rounds

Potential Sciences

EuropeDrug discoveryCambridge, England, United KingdomFounded 2025Private

Website · potentialsciences.com ↗

Runs gold-standard quantum chemistry (CCSD(T)) on GPUs, at what it says is a hundredth of the usual cost, to compute training data for atomistic models of how molecules bind and react, starting with small-molecule drug discovery for AI-first labs.

Disclosed total-
Rounds on record1
Latest roundeight-figure sum (capital and compute)Seed · 2026-11-05
Last stated valuationNone stated
Investors named10
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date2027Seed
Closed roundNot on the dollar scale (a range, or no rate)

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-11-05Seed
    Round

    eight-figure sum (capital and compute)

    Not stated

    The UK government's release; the investor list matches the company's own launch post, which calls Sovereign AI and Twin Path Ventures key investors. Pharmaphorum reports the two co-led; neither the government nor the company says lead. The fund adds compute on the AI Research Resource, Isambard-AI included, and does not disclose amounts.

    UK Sovereign AI FundTwin Path VenturesNauta CapitalOdysseyPortfolio VenturesBlue Wire CapitalRule30Lightfield EquityPatrick CollisonChris Gibson (Recursion)

    On the deal: Joséphine Kant (Investment Partner, UK Sovereign AI Fund)

    Announced by the company · gov.uk ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.